Citadel Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History

Citadel Advisors’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,300	Closed	-$278K	–	11100
2020 Q2	$278K	Sell	20,300 -1,400	-6%	-$21.6K	﹤0.01%	8037
2020 Q1	$310K	Buy	21,700 +7,800	+56%	+$128K	﹤0.01%	7288
2019 Q4	$235K	Sell	13,900 -22,900	-62%	-$426K	﹤0.01%	7956
2019 Q3	$566K	Sell	36,800 -10,500	-22%	-$224K	﹤0.01%	6541
2019 Q2	$1.11M	Buy	47,300 +26,200	+124%	+$647K	﹤0.01%	5528
2019 Q1	$598K	Buy	21,100 +3,700	+21%	+$108K	﹤0.01%	6489
2018 Q4	$524K	Sell	17,400 -19,800	-53%	-$555K	﹤0.01%	6324
2018 Q3	$1.3M	Buy	37,200 +28,000	+304%	+$847K	﹤0.01%	5090
2018 Q2	$218K	Buy	+9,200	New	+$220K	﹤0.01%	7757

Citadel Advisors's AKCA Position: Q4 2020 in Review

Citadel Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 25,890 shares — an estimated $470K sold.

Citadel Advisors first reported a position in AKCA in Q2 2018 and held it in 10 quarters. The position peaked at $17.8M in Q1 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

Citadel Advisors reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 25,890 Akcea Therapeutics Inc shares in Q4 2020, an estimated $470K.
Citadel Advisors first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 10 quarters.
Citadel Advisors's Akcea Therapeutics Inc position peaked at $17.8M in Q1 2019.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.